Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions: Obinutuzumab, Bendamustine, Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 15
States / cities: Tempe, Arizona • Denver, Colorado • Kansas City, Missouri + 12 more

Conditions: Lung Cancer Screening
Interventions: Sybil Artificial Intelligence (AI) screening; Diagnostic Test
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 50 Years to 80 Years
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2038
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Cognitive Training, Anxiety Disorders
Interventions: Cognitive Training Program; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 8 Years to 12 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Amputation; Traumatic, Leg, Lower
Interventions: Tap dance program; Other
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Stuttering, Developmental, Dyslexia, Healthy Participants
Interventions: Unpredictable auditory feedback perturbation: 2 behavioral sessions, Unpredictable auditory feedback perturbation during tCS: 3 behavioral sessions, Sustained F1 auditory feedback perturbation, Sustained F0 auditory feedback perturbation, Reflexive somatosensory perturbation, Anodal tCS targeting pSTG and vSSC, Anodal tCS targeting left or right vPMC, Sham tCS targeting pSTG or vSSC, Sham tCS targeting left vPMC or right vPMC; Behavioral · Other
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK2838232, Cobicistat; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 8 more

Conditions: Posttraumatic Stress Disorder
Interventions: Building Resilience after Childhood Emergencies (BRACE); Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 8 Years to 13 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Healthy
Interventions: Control Capsules, Mars Cocoa Extract Capsules; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 30 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Davis, California

Conditions: Sarcoma
Interventions: doxorubicin hydrochloride, trabectedin, laboratory biomarker analysis, quality-of-life assessment; Drug · Other · Procedure
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 8
States / cities: Santa Monica, California • Stanford, California • Iowa City, Iowa + 4 more

Conditions: Pancreatic Neoplasms
Interventions: Gemcitabine, AG-013736; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 17
States / cities: Antioch, California • Berkeley, California • Concord, California + 11 more

Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: everolimus, lapatinib ditosylate; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 6
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 3 more

Conditions: Sarcoma, Soft Tissue
Interventions: Olaratumab, Doxorubicin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more

Conditions: Vomiting, Migraines
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Up to 21 Years
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Gastrointestinal Neoplasms, Ovarian Neoplasms
Interventions: Gemcitabine; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hematologic Neoplasms
Interventions: CC-90002, Rituximab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 5
States / cities: Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 2 more

Conditions: Solid Tumors
Interventions: LBH589, Paclitaxel, Carboplatin, Bevacizumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pregnancy
Interventions: Fetal Monitoring Device, Investigational Fetal Monitoring Device; Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: Lymphoma, Advanced Solid Tumors
Interventions: E7766; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: New Haven, Connecticut • Miami, Florida • Boston, Massachusetts + 1 more

Conditions: Melanoma
Interventions: BMS-982470 (recombinant interleukin-21), Ipilimumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Scottsdale, Arizona • Los Angeles, California • Tampa, Florida + 5 more

Conditions: Breast Cancer
Interventions: Alloderm RTU, Cortiva 1mm Allograft Dermis, Skin or nipple-sparing mastectomy, Breast Q, Surgery; Other · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 22 Years to 70 Years · Female only
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer, Lung Cancer, Pulmonary Cancer, Non-Small-Cell Lung Carcinoma, Prostate Cancer, Prostatic Cancer, Gastric Cancer, Stomach Cancer
Interventions: MGCD0103 & Docetaxel; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: TGCT
Interventions: Emactuzumab, Placebo; Drug
Lead sponsor: SynOx Therapeutics Limited; Industry
Eligibility: 12 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: Beverly Hills, California • Los Angeles, California • Columbus, Ohio + 2 more

Conditions: Healthy, Hepatic Impairment
Interventions: T-817MA; Drug
Lead sponsor: FUJIFILM Toyama Chemical Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Non-small Cell Lung Cancer
Interventions: Blueberry powder; Dietary Supplement
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Louisville, Kentucky

Search by objective public record fields.

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)

Novel Anxiety Treatment

Tap Dance for Adults With Lower Limb Amputation

Investigating Individual Differences in Speech Motor Skills in Neurotypical Speakers and Persons With Disordered Speech

Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults

Building Resilience After Childhood Emergencies (BRACE)

Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 2

Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer

S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma

Genetic Analysis of Children With Cyclic Vomiting Syndrome (CVS) and Migraines

Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors

Maternal Fetal Device Performance Singleton

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Compare Outcomes Between Two Acellular Dermal Matrices

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

PK Study of T-817 in Subjects With Hepatic Impairment

Standard Chemotherapy With Blueberry Powder in Non-Small Cell Lung Cancer